Rallybio Corporation (RLYB)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 36/100 (MEDIUM), 21.3 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 1.76% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?
- Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
- RallyBio tries again for reverse merger, this time with Avenzo
- VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
- Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing
- Stock Splits Matter: Notable Splits in 2025 and What’s Happening in 2026
- Rallybio to acquire Candid Therapeutics
- Candid, in a reverse merger with RallyBio, to go public
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. — Pain 2020 Nov PMID 32520773
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Rallybio Corporation.
Full RLYB Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.